No Photo Available

Last Update

2016-11-15T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Blair Jobe?

Dr. Blair A. Jobe

HQ Phone: (877) 660-6777

Email: b***@***.org

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Allegheny Health Network

320 East North Avenue

Pittsburgh, Pennsylvania 15212

United States

Company Description

Allegheny Health Network (AHN.ORG), part of Highmark Health, is an integrated healthcare delivery system serving the Western Pennsylvania region. The Network is comprised of eight hospitals, including its flagship academic medical center Allegheny General ... more

Find other employees at this company (2,444)

Background Information

Employment History

Contributor

prweb

Centers for Rehab Services

Professor of Surgery, Department of Cardiothoracic Surgery

University of Pittsburgh

Director of Esophageal Research

UPMC

Surgeon

Canonsburg

Clinical Investigator

BARRX Medical , Inc.

Affiliations

Scientific Advisor
EndoStim Inc

Clinical Advisory Board
NinePoint Medical , Inc.

Founder
Barrett

Founder
Barrett’s Esophagus Risk Consortium

Education

M.D.

McGowan Institute for Regenerative Medicine

M.D.

University of Pittsburgh School of Medicine

bachelor’s degree

Loyola Marymount University

medical degree

Creighton University

Web References (188 Total References)


Press Release: Quansys Biosciences & Allegheny Health Network Collaboration | Quansys Biosciences

www.quansysbio.com [cached]

Blair Jobe, MD, a surgical oncologist and Director of Allegheny Health Network's Esophageal and Thoracic Institute, investigated four potential biomarkers associated with esophageal cancer. This panel, called B-AMP, (biglycan, myeloperoxidase, annexin-A6 and protein S100-A9) showed clinical significance in the early diagnosis of Gastroesophageal Reflux Disease, Barrett's Esophagus, Dysplasia and Esophageal Cancer. Dr. Jobe's findings were recently published in Cancer, a journal of the American Cancer Society.

...
"This discovery represents a major step forward in not only early detection but also the management of esophageal cancer," said Dr. Jobe.


The researchers, led by Blair ...

www.oncology-central.com [cached]

The researchers, led by Blair Jobe of Allegheny Health Network (PA, USA), found that this noninvasive low-cost blood test was able to identify esophageal cancer with an accuracy of 87%.

Incidence of this often deadly cancer has increased 600% since the 1970s. Survival is likely to be longer if the disease is diagnosed at an early stage, yet it often goes undetected as symptoms are not obvious in the early stages. The identification of valid blood-based biomarkers could improve early detection of the disease, but previous efforts have met difficulty in identifying a single conserved and universal tracking marker.
"Esophageal cancer patients often have few options available to fight this disease, and 5-year survival rates are extremely low at about 15%," commented Jobe (Allegheny Health Network).


PITTSBURGH?A research team led ...

www.endonurse.com [cached]

PITTSBURGH?A research team led by Allegheny Health Network surgical oncologist Blair Jobe, MD, has developed and validated a four-protein serum biomarker panel that holds significant promise for early detection of esophageal cancer, a relatively rare but often deadly disease that has grown in incidence over the past several decades.

Dr. Jobe's findings were published online in Cancer, a journal of the American Cancer Society.
The four-protein panel, called B-AMP (biglycan, myeloperoxidase, annexin-A6 and protein S100-A9), is a simple, non-invasive, low-cost blood test, that identified esophageal cancer with a high classification accuracy of 87 percent in the study.
The discovery represents a major step forward in not only early detection but also the management of esophageal cancer, said Dr. Jobe, Director of Allegheny Health Network's Esophageal and Thoracic Institute. The test is already being used at the Institute in a clinical trial setting to monitor the course of esophageal cancer.
"Esophageal cancer patients often have few options available to fight this disease, and five-year survival rates are extremely low at about 15 percent," said Dr. Jobe.


"Oesophageal cancer patients often have ...

www.ncah.com.au [cached]

"Oesophageal cancer patients often have few options available to fight this disease, and five-year survival rates are extremely low at about 15 per cent," Blair Jobe, director of Allegheny Health Network's Oesophageal and Thoracic Institute and the study's lead researcher, said in a statement.


Blair Jobe ...

www.prweb.com [cached]

Blair Jobe MD

...
A research team led by Allegheny Health Network surgical oncologist Blair Jobe, MD, has developed and validated a four-protein serum biomarker panel that holds significant promise for early detection of esophageal cancer, a relatively rare but often deadly disease that has grown in incidence over the past several decades.
Dr. Jobe's findings were published online today in Cancer, a journal of the American Cancer Society.
The four-protein panel, called B-AMP (biglycan, myeloperoxidase, annexin-A6 and protein S100-A9), is a simple, non-invasive, low-cost blood test, that identified esophageal cancer with a high classification accuracy of 87 percent in the study.
The discovery represents a major step forward in not only early detection but also the management of esophageal cancer, said Dr. Jobe, Director of Allegheny Health Network's Esophageal and Thoracic Institute. The test is already being used at the Institute in a clinical trial setting to monitor the course of esophageal cancer, providing physicians with guidance on response to therapy or early notification of a recurrence and allowing them to pursue different or more aggressive therapies, if necessary.
"Esophageal cancer patients often have few options available to fight this disease, and five-year survival rates are extremely low at about 15 percent," said Dr. Jobe.
...
Followed by novel mathematical modeling, Dr. Jobe's team was able to combine relevant and strong individual biomarkers into a panel that is accurate and reliable in detecting esophageal cancer.
...
"Dr. Jobe's research shows the value of our approach to working collaboratively and across the full spectrum of disease," said David Parda, MD, System Chair, Allegheny Health Network Cancer Institute.

Similar Profiles

Other People with this Name

Other people with the name Jobe

Kathryn Jobe
Leidos Holdings, Inc.

Robert Jobe
OpenWorks

Muhammed Jobe
Marrelli Support Services Inc

Jennifer Jobe
Bickmore Risk Services

Tom Jobe
SensiQ Technologies Inc

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory